Past, present, and future clinical trials using ribavirin in cancer
| Clinical trials | ID number | Status as of December 2018 | Condition | Treatment | Phase | References |
|---|---|---|---|---|---|---|
| Low-dose Peg-interferon plus ribavirin (IFN/RBV) for prevention of hepatocellular carcinoma (HCC) recurrence in patients who had surgery to remove primary HCC | NCT00375661 | Completed | Hepatocellular carcinoma | Interferon-alfa-2b, ribavirin | 4 | NA |
| A study of ribavirin to treat M4 and M5 acute myelocytic leukemia | NCT00559091 | Completed | Acute myeloid leukemia | Ribavirin | 2 | (6) |
| Effect of biological therapy on biomarkers in patients with untreated hepatitis C, metastatic melanoma, or Crohn disease | NCT00897312 | Terminated | Melanoma | Infliximab, pegylated-interferon alfa, ticilimumab, ribavirin | NA | NA |
| Use of ribavirin and low-dose ara-C to treat acute myeloid leukemia | NCT01056523 | Completed (has results) | Acute myeloid leukemia | Ribavirin, cytarabine arabinoside | 1–2 | (6, 7) |
| Treatment with ribavirin for patients with metastatic breast cancer | NCT01056757 | Terminated | Breast cancer | Ribavirin | 1–2 | NA |
| Peg-interferon plus ribavirin for hepatitis C patients concomitant with hepatocellular carcinoma | NCT00834860 | Unknown | Hepatocellular carcinoma | Peg-interferon alpha-2a, ribavirin | 4 | (26) |
| Phase I/II study of ribavirin given as monotherapy in solid tumor cancer patients | NCT01309490 | Unknown | Malignant solid tumor | Ribavirin | 1–2 | NA |
| Ribavirin and Hedgehog inhibitor with or without decitabine in AML | NCT02073838 | Recruiting | Acute myeloid leukemia | Ribavirin, Hedegehog inhibitor, decitabine | 2 | NA |
| Study of decitabine in combination with sequential rapamycin or ribavirin in high-risk AML patients (AML) | NCT02109744 | Recruiting | Acute myeloid leukemia | Decitabine, rapamycin, ribavirin | 1–2 | NA |
| Oral hepatitis C treatment for indolent lymphoma (OPTImaL) study (Optimal) | NCT02717949 | Terminated (results submitted) | Lymphoma | Sofosbuvir, ledipasvir, ribavirin | 4 | NA |
| Impact of interferon free regimens in patients with chronic HCV and successfully treated HCC (FRI-STC) | NCT02771405 | Recruiting | Hepatocellular carcinoma | Sofosbuvir, ribavirin, simeprevir, daclatasvir, ledipasvir | 3 | (29) |
| Sofosbuvir + ledipasvir ± ribavirin and sofosbuvir + ribavirin for pts with indolent B-cell lymphoma associated with HCV infection | NCT02836925 | Recruiting | B-Cell lymphoma | Sofosbuvir, ledipasvir, ribavirin | 2 | NA |
| Pharmacodynamic effects of ribavirin in patients with tonsil and/or base of tongue squamous cell carcinoma | NCT01268579 | Active, not recruiting | Head and neck cancer | Ribavirin | NA | NA |
| Induction chemotherapy with afatinib, ribavirin, and weekly carboplatin/paclitaxel for stage IVA/IVB HPV-associated oropharynx squamous cell cancer (OPSCC) | NCT01721525 | Completed | Head and neck cancer | Afatinib, ribavirin, carboplatin/paclitaxel | 1 | (15) |
| Peg-interferon plus ribavirin for hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma | NCT00630084 | Completed | Neoplasms | Peg-interferon alpha-2a, ribavirin | 4 | NA |
| A pilot investigator-initiated study of ribavirin in indolent follicular lymphoma and mantle cell lymphoma | NCT03585725 | Recruiting | Follicular/mantle cell lymphoma | Ribavirin | 1 | NA |
| A clinical study to evaluate the efficacy and safety of docetaxel with ribavirin in patients with progressive castration-resistant prostate cancer who have previously received docetaxel alone | UMIN 000012521 | Completed | Castration-resistant prostate cancer | Ribavirin, docetaxel | 1–2 | (43) |
| A phase 1/2a trial of docetaxel plus ribavirin for reprogramming efficacy in patients with progressive metastatic castration-resistant prostate cancer who previously received docetaxel alone: DRREEM trial | UMIN 000021107 | Completed | Castration-resistant prostate cancer | Ribavirin, docetaxel | 1–2 | (46) |
| Ribavirin for patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-related malignancies | NCT02308241 | Active, not recruiting | HPV-Related malignancies | Ribavirin | NA | NA |